Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Alzheimer's Research & Therapy
Published in: Alzheimer's Research & Therapy 5-8/2014

Open Access 01-10-2014 | Research

Comorbidity profile in dementia with Lewy bodies versus Alzheimer’s disease: a linkage study between the Swedish Dementia Registry and the Swedish National Patient Registry

Authors: Seyed-Mohammad Fereshtehnejad, Soheil Damangir, Pavla Cermakova, Dag Aarsland, Maria Eriksdotter, Dorota Religa

Published in: Alzheimer's Research & Therapy | Issue 5-8/2014

Login to get access

Abstract

Introduction

Compared to Alzheimer’s disease (AD), dementia with Lewy bodies (DLB) is usually associated with a more complex clinical picture and higher burden of care. Yet, few investigations have been performed on comorbidities and risk factors of DLB. Therefore, we aimed to compare clinical risk factors and comorbidity profile in DLB and AD patients using two nationwide registries.

Methods

This is a linkage study between the Swedish dementia registry (SveDem) and the Swedish National Patient Registry conducted on 634 subjects with DLB and 9161 individuals with AD registered during the years 2007–2012. Comorbidity profile has been coded according to the International Classification of Diseases version 10 (ICD 10) in addition to the date of each event. The main chapters of the ICD-10, the Charlson score of comorbidities and a selected number of neuropsychiatric diseases were compared between the DLB and AD groups. Comorbidity was registered before and after the dementia diagnosis.

Results

“Mental and behavioral disorders”, “diseases of the nervous system”, “diseases of the eye and adnexa”, diseases of the “circulatory”, “respiratory”, and “genitourinary” systems, “diseases of the skin and subcutaneous tissue” and “diseases of the musculoskeletal system and connective tissue” occurred more frequently in the DLB group after multivariate adjustment. Depression [adjusted OR = 2.12 (95%CI 1.49 to 3.03)] and migraine [adjusted OR = 3.65 (95%CI 1.48 to 9.0)] were more commonly recorded before the diagnosis of dementia in the DLB group. Following dementia diagnosis, ischemic stroke [adjusted OR = 1.89 (95%CI 1.21 to 2.96)] was more likely to happen among the DLB patients compared to the AD population.

Conclusions

Our study indicated a worse comorbidity profile in DLB patients with higher occurrence of depression, stroke and migraine compared with the AD group. Deeper knowledge about the underlying mechanisms of these associations is needed to explore possible reasons for the different pattern of comorbidity profile in DLB compared to AD and their prognostic significance.
Appendix
Available only for authorised users
Literature
1.
Kalra S, Bergeron C, Lang AE: Lewy body disease and dementia. A review. Arch Intern Med. 1996, 156: 487-493. 10.1001/archinte.1996.00440050031004.PubMedCrossRef
2.
Vossius C, Testad I, Skjaeveland R, Nesvag S: The use and costs of health and social services in patients with longstanding substance abuse. BMC Health Serv Res. 2013, 13: 185-10.1186/1472-6963-13-185.PubMedPubMedCentralCrossRef
3.
Oesterhus R, Soennesyn H, Rongve A, Ballard C, Aarsland D, Vossius C: Long-term mortality in a cohort of home-dwelling elderly with mild Alzheimer’s disease and Lewy body dementia. Dement Geriatr Cogn Disord. 2014, 38: 161-169. 10.1159/000358051.PubMedCrossRef
4.
Rongve A, Vossius C, Nore S, Testad I, Aarsland D: Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer’s dementia. Int J Geriatr Psychiatry. 2014, 29: 392-398. 10.1002/gps.4015.PubMedCrossRef
5.
Gill DP, Hubbard RA, Koepsell TD, Borrie MJ, Petrella RJ, Knopman DS, Kukull WA: Differences in rate of functional decline across three dementia types. Alzheimers Dement. 2013, 9: S63-S71. 10.1016/j.jalz.2012.10.010.PubMedPubMedCentralCrossRef
6.
Espallargues M, Philp I, Seymour DG, Campbell SE, Primrose W, Arino S, Dunstan E, Lamura G, Lawson P, Mestheneos E, Politynska B, Raiha I: Measuring case-mix and outcome for older people in acute hospital care across Europe: the development and potential of the ACMEplus instrument. QJM. 2008, 101: 99-109. 10.1093/qjmed/hcm136.PubMedCrossRef
7.
Garcia-Ptacek S, Farahmand B, Kareholt I, Religa D, Cuadrado ML, Eriksdotter M: Mortality risk after dementia diagnosis by dementia type and underlying factors: a cohort of 15,209 patients based on the Swedish dementia registry. J Alzheimers Dis. 2014, 41: 467-477.PubMed
8.
Ballard C, Holmes C, McKeith I, Neill D, O’Brien J, Cairns N, Lantos P, Perry E, Ince P, Perry R: Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease. Am J Psychiatry. 1999, 156: 1039-1045.PubMed
9.
Boot BP, Orr CF, Ahlskog JE, Ferman TJ, Roberts R, Pankratz VS, Dickson DW, Parisi J, Aakre JA, Geda YE, Knopman DS, Petersen RC, Boeve BF: Risk factors for dementia with Lewy bodies: a case-;control study. Neurology. 2013, 81: 833-840. 10.1212/WNL.0b013e3182a2cbd1.PubMedPubMedCentralCrossRef
10.
Sadak TI, Katon J, Beck C, Cochrane BB, Borson S: Key neuropsychiatric symptoms in common dementias: prevalence and implications for caregivers, clinicians, and health systems. Res Gerontol Nurs. 2014, 7: 44-52. 10.3928/19404921-20130918-01.PubMedPubMedCentralCrossRef
11.
Fritze F, Ehrt U, Hortobagyi T, Ballard C, Aarsland D: Depressive symptoms in Alzheimer’s disease and lewy body dementia: a one-year follow-up study. Dement Geriatr Cogn Disord. 2011, 32: 143-149. 10.1159/000332016.PubMedCrossRef
12.
13.
Religa D, Spangberg K, Wimo A, Edlund AK, Winblad B, Eriksdotter-Jonhagen M: Dementia diagnosis differs in men and women and depends on age and dementia severity: data from SveDem, the Swedish Dementia Quality Registry. Dement Geriatr Cogn Disord. 2012, 33: 90-95. 10.1159/000337038.PubMedCrossRef
14.
Skoldunger A, Wimo A, Johnell K: Net costs of dementia in Sweden – an incidence based 10–year simulation study. Int J Geriatr Psychiatry. 2012, 27: 1112-1117. 10.1002/gps.2828.PubMedCrossRef
15.
The ICD-10 Classification of Mental and Behavioral Disorders: Diagnostic Criteria for Research. 1993, World Health Organization, Geneva
16.
McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005, 65: 1863-1872. 10.1212/01.wnl.0000187889.17253.b1.PubMedCrossRef
17.
Folstein MF, Folstein SE, McHugh PR: Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12: 189-198. 10.1016/0022-3956(75)90026-6.PubMedCrossRef
18.
Razavi D, Ljung R, Lu Y, Andren-Sandberg A, Lindblad M: Reliability of acute pancreatitis diagnosis coding in a National Patient Register: a validation study in Sweden. Pancreatology. 2011, 11: 525-532. 10.1159/000331773.PubMedCrossRef
19.
Armitage JN, van der Meulen JH: Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score. Br J Surg. 2010, 97: 772-781. 10.1002/bjs.6930.PubMedCrossRef
20.
Gordon M, Stark A, Skoldenberg OG, Karrholm J, Garellick G: The influence of comorbidity scores on re-operations following primary total hip replacement: comparison and validation of three comorbidity measures. Bone Joint J. 2013, 95-B: 1184-1191. 10.1302/0301-620X.95B9.31006.PubMedCrossRef
21.
Fereshtehnejad SM, Religa D, Westman E, Aarsland D, Lokk J, Eriksdotter M: Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson’s disease with dementia: data from the Swedish Dementia Quality Registry (SveDem). Neuropsychiatr Dis Treat. 2013, 9: 927-935. 10.2147/NDT.S45840.PubMedPubMedCentralCrossRef
22.
McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000, 356: 2031-2036. 10.1016/S0140-6736(00)03399-7.PubMedCrossRef
23.
Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, Wang C, Tan MS, Tan L: Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2014, ?: ?-[Epub ahead of print]
24.
Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, Leroi I, Pozo-Rodriguez F, Minthon L, Londos E: Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009, 8: 613-618. 10.1016/S1474-4422(09)70146-2.PubMedCrossRef
25.
Andreasen P, Lonnroos E, von Euler-Chelpin MC: Prevalence of depression among older adults with dementia living in low- and middle-income countries: a cross-sectional study. Eur J Pub Health. 2014, 24: 40-44. 10.1093/eurpub/ckt014.CrossRef
26.
Iranzo A, Gelpi E, Tolosa E, Molinuevo JL, Serradell M, Gaig C, Santamaria J: Neuropathology of prodromal Lewy body disease. Mov Disord. 2014, 29: 410-415. 10.1002/mds.25825.PubMedCrossRef
27.
Chuang CS, Lin CL, Lin MC, Sung FC, Kao CH: Migraine and risk of dementia: a nationwide retrospective cohort study. Neuroepidemiology. 2013, 41: 139-145. 10.1159/000353559.PubMedCrossRef
28.
Gudmundsson LS, Scher AI, Sigurdsson S, Geerlings MI, Vidal JS, Eiriksdottir G, Garcia MI, Harris TB, Kjartansson O, Aspelund T, van Buchem MA, Gudnason V, Launer LJ: Migraine, depression, and brain volume: the AGES-Reykjavik Study. Neurology. 2013, 80: 2138-2144. 10.1212/WNL.0b013e318295d69e.PubMedPubMedCentralCrossRef
29.
Hagen K, Stordal E, Linde M, Steiner TJ, Zwart JA, Stovner LJ: Headache as a risk factor for dementia: a prospective population-based study. Cephalalgia. 2014, 34: 327-335. 10.1177/0333102413513181.PubMedCrossRef
30.
Manford M, Andermann F: Complex visual hallucinations. Clinical and neurobiological insights. Brain. 1998, 121: 1819-1840. 10.1093/brain/121.10.1819.PubMedCrossRef
31.
Demarquay G, Ryvlin P, Royet JP: Olfaction and neurological diseases: a review of the literature. Rev Neurol. 2007, 163: 155-167. 10.1016/S0035-3787(07)90387-2.PubMedCrossRef
32.
Ballard C, O’Sullivan MJ: Alzheimer disease and stroke: cognitive and neuroimaging predictors of AD and stroke. Nat Rev Neurol. 2013, 9: 605-606. 10.1038/nrneurol.2013.215.PubMedCrossRef
33.
Jellinger KA: Prevalence of vascular lesions in dementia with Lewy bodies. A postmortem study. J Neural Transm. 2003, 110: 771-778. 10.1007/s00702-003-0822-z.PubMedCrossRef
34.
Isojima D, Togo T, Kosaka K, Fujishiro H, Akatsu H, Katsuse O, Iritani S, Matsumoto T, Hirayasu Y: Vascular complications in dementia with Lewy bodies: a postmortem study. Neuropathology. 2006, 26: 293-297. 10.1111/j.1440-1789.2006.00699.x.PubMedCrossRef
35.
Mendel T, Bertrand E, Szpak GM, Stepien T, Wierzba-Bobrowicz T: Complications of severe cerebral amyloid angiopathy in the course of dementia with Lewy bodies. A case report. Folia Neuropathol. 2010, 48: 293-299.PubMed
36.
Wu E, Lipton RB, Dickson DW: Amyloid angiopathy in diffuse Lewy body disease. Neurology. 1992, 42: 2131-2135. 10.1212/WNL.42.11.2131.PubMedCrossRef
37.
Dugger BN, Adler CH, Shill HA, Caviness J, Jacobson S, Driver-Dunckley E, Beach TG: Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord. 2014, 20: 525-529. 10.1016/j.parkreldis.2014.02.012.PubMedPubMedCentralCrossRef
38.
Herrmann N, Mamdani M, Lanctot KL: Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004, 161: 1113-1115. 10.1176/appi.ajp.161.6.1113.PubMedCrossRef
39.
Jaussent I, Ancelin ML, Berr C, Peres K, Scali J, Besset A, Ritchie K, Dauvilliers Y: Hypnotics and mortality in an elderly general population: a 12-year prospective study. BMC Med. 2013, 11: 212-10.1186/1741-7015-11-212.PubMedPubMedCentralCrossRef
40.
Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbaek G: Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. Am J Geriatr Psychiatry. 2014, 22: 321-331. 10.1016/j.jagp.2013.06.007.PubMedCrossRef
41.
Rochon PA, Normand SL, Gomes T, Gill SS, Anderson GM, Melo M, Sykora K, Lipscombe L, Bell CM, Gurwitz JH: Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med. 2008, 168: 1090-1096. 10.1001/archinte.168.10.1090.PubMedCrossRef
42.
43.
Johnell K, Religa D, Eriksdotter M: Differences in drug therapy between dementia disorders in the Swedish dementia registry: a nationwide study of over 7,000 patients. Dement Geriatr Cogn Disord. 2013, 35: 239-248. 10.1159/000348408.PubMedCrossRef
44.
Fereshtehnejad SM, Johnell K, Eriksdotter M: Anti-dementia drugs and co-medication among patients with Alzheimer’s disease: investigating real-world drug use in clinical practice using the Swedish Dementia Quality Registry (SveDem). Drugs Aging. 2014, 31: 215-224. 10.1007/s40266-014-0154-8.PubMedCrossRef
45.
Gustafsson M, Karlsson S, Gustafson Y, Lovheim H: Psychotropic drug use among people with dementia-;a six-month follow-up study. BMC Pharmacol Toxicol. 2013, 14: 56-10.1186/2050-6511-14-56.PubMedPubMedCentralCrossRef
46.
Johnell K, Fastbom J: Comparison of prescription drug use between community-dwelling and institutionalized elderly in Sweden. Drugs Aging. 2012, 29: 751-758. 10.1007/s40266-012-0002-7.PubMedCrossRef
47.
Cermakova P, Fereshtehnejad SM, Johnell K, Winblad B, Eriksdotter M, Religa D: Cardiovascular medication burden in dementia disorders: a nationwide study of 19,743 dementia patients in the Swedish Dementia Registry. Alzheimers Res Ther. 2014, 6: 34-10.1186/alzrt264.PubMedPubMedCentralCrossRef
48.
Cermakova P, Eriksdotter M, Lund LH, Winblad B, Religa P, Religa D: Heart failure and Alzheimer’s disease. J Intern Med. 2014, ?: ?-[Epub ahead of print]PubMedPubMedCentral
49.
Magaki S, Yong WH, Khanlou N, Tung S, Vinters HV: Comorbidity in dementia: update of an ongoing autopsy study. J Am Geriatr Soc. 2014, 62 (9): 1722-1728. 10.1111/jgs.12977.PubMedPubMedCentralCrossRef
50.
Imfeld P, Brauchli Pernus YB, Jick SS, Meier CR: Epidemiology, co-morbidities, and medication use of patients with Alzheimer’s disease or vascular dementia in the UK. J Alzheimers Dis. 2013, 35: 565-573.PubMed
51.
Hill JW, Futterman R, Duttagupta S, Mastey V, Lloyd JR, Fillit H: Alzheimer’s disease and related dementias increase costs of comorbidities in managed Medicare. Neurology. 2002, 58: 62-70. 10.1212/WNL.58.1.62.PubMedCrossRef
52.
Eaker ED, Mickel SF, Chyou PH, Mueller-Rizner NJ, Slusser JP: Alzheimer’s disease or other dementia and medical care utilization. Ann Epidemiol. 2002, 12: 39-45. 10.1016/S1047-2797(01)00244-7.PubMedCrossRef
53.
Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO: External review and validation of the Swedish national inpatient register. BMC Public Health. 2011, 11: 450-10.1186/1471-2458-11-450.PubMedPubMedCentralCrossRef
54.
Metadata
Title
Comorbidity profile in dementia with Lewy bodies versus Alzheimer’s disease: a linkage study between the Swedish Dementia Registry and the Swedish National Patient Registry
Authors
Seyed-Mohammad Fereshtehnejad
Soheil Damangir
Pavla Cermakova
Dag Aarsland
Maria Eriksdotter
Dorota Religa
Publication date
01-10-2014
Publisher
BioMed Central
Published in
Alzheimer's Research & Therapy / Issue 5-8/2014
Electronic ISSN: 1758-9193
DOI
https://doi.org/10.1186/s13195-014-0065-2

Other articles of this Issue 5-8/2014

Alzheimer's Research & Therapy 5-8/2014 Go to the issue

Debate

Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?

Research

β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage

Research

Transcranial magnetic stimulation and transcranial direct current stimulation: treatments for cognitive and neuropsychiatric symptoms in the neurodegenerative dementias?

Research

PLD3 is accumulated on neuritic plaques in Alzheimer’s disease brains

Research

Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an 11C altropane positron emission tomography study

Erratum

Erratum to: Cardiovascular medication burden in dementia disorders: a nationwide study of 19, 743 dementia patients in the Swedish Dementia Registry